Trial Profile
Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Aphasia; Lewy body disease; Mild cognitive impairment; Multiple system atrophy; Neurodegenerative disorders; Parkinson's disease; Progressive supranuclear palsy
- Focus Diagnostic use
- Acronyms PET Tau
- 22 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 22 Aug 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2025.
- 24 Mar 2022 Planned number of patients changed from 120 to 300.